Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN‐812 (Viloxazine Extended‐Release) Pharmacokinetics in Healthy Adults

por Wang, Zhao, Kosheleff, Alisa R., Adeojo, Lilian W., Odebo, Oyinkansola, Adewole, Toyin, Qin, Peibing, Maletic, Vladimir, Schwabe, Stefan, Nasser, Azmi
Publicado 2021

Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder

por Nasser, Azmi, Kosheleff, Alisa R., Hull, Joseph T., Liranso, Tesfaye, Qin, Peibing, Busse, Gregory D., Fava, Maurizio, Maletic, Vladimir, Rubin, Jonathan, Lopez, Frank
Publicado 2021

Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinic...

por Nasser, Azmi, Kosheleff, Alisa R., Hull, Joseph T., Liranso, Tesfaye, Qin, Peibing, Busse, Gregory D., O'Neal, Welton, Fava, Maurizio, Faraone, Stephen V., Rubin, Jonathan
Publicado 2021